In this issue, guest editors bring their considerable expertise to this important topic.
Key Features
Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice.
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.
Author Information
Edited by Melissa Pilewskie, MD, FACS, Associate Professor of Surgery, Director of Breast Care, University of Michigan, Rogel Cancer Center
Breast Cancer Risk Reduction: Current Status and Emerging Trends to Increase Efficacy and Reduce Toxicity of Preventive Medication
Individualizing Breast Cancer Risk Assessment in Clinical Practice
How to Navigate the Treatment Spectrum from Multimodality Therapy to Observation Alone for ductal carcinoma in situ
Is Axillary Staging Obsolete in Early Breast Cancer?
Evidence-Based Strategies to Minimize the Likelihood of Axillary Lymph Node Dissection in Clinically Node-Positive Patients Following Neoadjuvant Chemotherapy
Managing the Morbidity: Individualizing Risk Assessment, Diagnosis, and Treatment Options for Upper Extremity Lymphedema
Incorporating Tumor Biology to Select Patients for the Omission of Radiation Therapy
Selecting Triple Negative Breast Cancer Patients for Immunotherapy
Fertility and Sexual Health in Young Women with Early-Stage Breast Cancer
Prepectoral Versus Subpectoral Implant-Based Reconstruction: How Do We Choose?
Incorporating Value-Based Decisions in Breast Cancer Treatment Algorithms
Addressing Inequalities in Breast Cancer Care Delivery
Lasting Impacts of the COVID-19 Pandemic on Breast Cancer Diagnosis and Treatment in the United States
